Introduction
Extracts of celastrol, a pentacyclic triterpenoid naturally occurring in the Chinese Thunder God vine Tripterygium wilflordii, are used in traditional Chinese medicine to treat fever, chills, joint pain and edema. Recent evidence suggests that celastrol may be a novel anti-obesity drug that mediates weight loss by acting as a leptin sensitizer (1) .
Beneficial actions of chronic celastrol treatment against obesity and diabetes were first described by Jung Kim and colleagues in 2013 (2) and corroborated by Weisberg et al. (3) in 2016, who observed lower body weight (BW) and blood glucose levels in leptin receptordeficient Lep db mice after treatment with 1 or 3 mg celastrol/kg BW, respectively. Because a single acute administration of intraperitoneal celastrol (3 mg/kg BW) improves glucose tolerance and insulin sensitivity in Lep db mice compared to pair-fed Lep db controls, the implication is that effects of celastrol on glucose homeostasis can be independent from the effects on body weight and body composition (3) .
There are several suggested mechanisms for celastrol's effects. Using 10-to 30-fold lower doses, Liu and colleagues reported celastrol to be a potent leptin sensitizer that inhibits food intake (FI), lowers body weight and improves glucose tolerance by reducing hypothalamic endoplasmatic reticulum (ER) stress in diet-induced obese, but not in lean mice or in leptin (receptor)-deficient Lep ob or Lep db mice (1) . Celastrol administration decreased hepatic steatosis via increased Sirt1 expression in mice (4) , and this led to impaired adipocyte differentiation but increased lipolysis in vitro in 3T3 adipocyte cells (5) . Celastrol has also been suggested to decrease body weight via the heat shock factor 1 (HSF1) -peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) axis and mitochondrial gene programs that lead to increased muscle and brown adipose tissue (BAT) thermogenesis and inguinal white adipose tissue (iWAT) browning (6) .
Celastrol has several confirmed molecular targets. It inhibits IKKα and IKKβ kinases by binding to a Cysteine (Cys) residue in the kinase activation loop (7) . Celastrol further inhibits the interaction of heat shock protein 90 (Hsp90) with co-chaperones such as cell division cycle 37 (Cdc37) by binding to Cys residues in Cdc37 (8, 9) or to the dimer interface of Hsp90 (10) , thereby destabilizing the Hsp90-Cdc37-IKK complex and inhibiting IKK signaling.
Additionally, celastrol has been found to directly inhibit proteasome activity (11) and to activate HSF1 and induce the heat shock response (12, 13) , but the molecular mechanisms are not known.
Leptin-sensitizing properties of celastrol have been attributed to a decrease in ER stress, but direct molecular underpinnings remain elusive (1).
Our goal was to interrogate celastrol-induced weight loss by assessing celastrol's leptinsensitizing molecular mechanism as well as its thermogenic potential. Special emphasis was
given to the roles of protein tyrosine phosphatase (PTP) 1B (PTP1B) as a negative regulator of leptin action, and to uncoupling protein 1 (UCP1) as a main driver for brown/beige fat thermogenesis. Our focus on PTP1B was driven by the following rationale: A recent experiment using triterpenoids reported inhibitory activity of celastrol towards several protein phosphatases including PTP1B (14) ; and PTP1B is a known feedback regulator of insulin and leptin signalling via dephosphorylation of Janus kinase 2 (JAK2) (15) , of the insulin receptor (IR) and of insulin receptor substrate 1 (IRS1) (16) . Our focus on UCP1 was driven by a recent report that attributed the weight-lowering effects of celastrol to the transcriptional activation of UCP1 with increased BAT activation, iWAT browning and elevated energy expenditure (6) .
Research design and methods

Animals
C57BL/6J mice were obtained from Janvier Labs (Saint-Berthevin Cedex, France Celastrol injections took place 1-2 h before dark onset. HFD-fed mice were injected with 100 µg/kg BW celastrol or vehicle 1-2 h before sacrifice. Mice were distributed into treatment groups based on their starting body weight in order to assure an equal distribution of starting body weights, allowing for better dissection of the effects of longitudinal treatments on body weight. In vivo experiments were performed without blinding of the investigators. All studies were based on power analyses to assure adequate sample sizes, and approved by the State of Bavaria, Germany.
Body composition and indirect calorimetry
Fat and lean masses were assessed using nuclear magnetic resonance (NMR) technology (EchoMRI, Houston, TX, USA). Energy expenditure, locomotor activity and exact food intake measurements were analyzed by a combined indirect calorimetry system (TSE System, Bad
Homburg, Germany). Mice were acclimatized to the calorimetry system for at least 24 h before data collection for 3 d and 21 h at 23°C. To assess the impact of celastrol on basal metabolic rates and maximum respiration, housing temperatures were changed to 30°C for 17 h. Mice were subsequently injected with 0.5 µg/g BW norepinephrine (Sigma-Aldrich, St. Louis, Missouri, USA) in 0.9% NaCl 2.5 h after light onset, and assessed for the maximum increase in energy expenditure observed within 1 h. We determined the basal metabolic rates of vehicle and celastrol-treated mice housed at 30°C by averaging energy expenditure values from 4.5 to 6.5 h after light onset, a period when mice displayed the lowest daily physical activity. For the measurement of maximum respiration, one mouse had to be excluded due to a missed norepinephrine injection, and one mouse had to be excluded from food intake analyses due to spillage.
Glucose-tolerance tests
Mice were treated for 6 d with celastrol (100 µg/kg body weight) or vehicle and then subjected to a glucose-tolerance test (GTT) on Day 7. After 6 h of fasting, 1.5 g glucose/kg body weight was injected ip and tail blood glucose was measured using a handheld glucometer (Freestyle freedom Lite, Abbott Diabetes Care, Alameda, CA, USA) before (0 min) and 15, 30, 60 and 120 min after glucose injection.
RNA isolation and qPCR analysis
RNA was isolated from tissue using a commercially available kit (Macherey-Nagel, Düren, Germany). Equal amounts of RNA were transcribed to cDNA using the QuantiTect Reverse Transcription kit (Qiagen, Hilden, Germany). Gene expression was analyzed using custom-made primers (Sigma, St Louis, MO, USA), TaqMan probes (Thermo Fischer Scientific, Inc., Rockford, IL USA) and SYBR Green TM or TaqMan mastermix (Applied Biosystem, Carlsbad, CA, USA). Gene expression was evaluated using the delta-delta Ct method and Hprt was used as the housekeeping gene. Primer pairs and TaqMan probes used are listed in the supplementary tables. Ct values for hypothalamic inflammatory markers were between 32 and 36. High purity nitrogen was used as desolvation gas and auxiliary gas, and argon was used as collision gas. The desolvation gas temperature and flow rate were 120°C and 200 l/h, respectively. The cone gas flow rate was 50 l/h. The source temperature was 100°C. The collision energy was 25 eV. The instrumentation ran in full-scan mode with the Q-TOF data collected over the range 100 -1000 m/z with a scan time of 2 s and inter scan time of 0.1 s.
Western blotting and densitometric analyses
Data acquisition and processing were performed on the QuanLynx Application Manager software (Waters-Micromass, Manchester, UK). The stability of celastrol was calculated based on the ratio between peak area internal standard (IS) divided by peak area celastrol. Every experiment was repeated in duplicates.
H-NMR
A 10 mM (4.5g/ml) stock solution of celastrol in pure DMSO-d6 was prepared. From this stock the following solutions were prepared: (a) celastrol at a final concentration of 177.5 µM (0.08 mg/ml) in DMSO-d6; (b) celastrol in PBS with 50% DMSO-d6; (c) celastrol in PBS with 10% DMSO-d6 and (d) celastrol in PBS with 5% DMSO-d6. The sample of 177.5 µM celastrol in DMSO-d6 was used as reference where the solubility of celastrol is considered 100%.
Subsequently, aliquots of all samples were incubated at 37 °C, and measured at day 0, 7 and 14.
Samples were then subjected to one-dimensional (1D) 1 H-NMR at 37°C on a Bruker 600 MHz spectrometer equipped with a cryogenic QCI-probehead ( 1 H, 31 P, 13 C, 15 N) equipped with Zgradients. 1D 1 H experiments were performed using a WATERGATE pulse sequence with 19k time domain and 128 scans using 177.5 µM celastrol samples in 100% DMSO-d6 and in PBS buffer pH 7.4 and 5%/10%/50% DMSO-d6. The solubility of celastrol was calculated based on the ratio between peak intensity of the aromatic proton 6 of celastrol in pure DMSO-d6 at time 0 divided by peak intensity of the same celastrol proton in PBS solution.
Statistical Analyses
Statistical analyses were performed using GraphPad Prism (GraphPad Software, Inc. La Jolla, CA, USA) or SPSS (IBM, Armonk, NY, USA). Untailed student's t-test or two-way ANOVA with Bonferroni's post test were applied to compare differences between phenotypes. Combined indirect calorimetry measurements were assessed by Analysis of Co-Variance (ANCOVA), using lean and fat mass as covariates. P-values lower than 0.05 were considered significant.
Significances were indicated as follow: * /+ p < 0.05, ** /++ p < 0.01, *** /+++ p < 0.001, **** /++++ p<0.0001. All results are presented as means +/-SEM.
Results
Celastrol has compromised stability in aqueous solutions
To evaluate celastrol as weight loss agent in DIO mice, we first aimed to determine a formulation suitable for chronic in vivo injection studies. NMR revealed highest stability and solubility when celastrol was dissolved in pure DMSO-d6 ( Supplementary Fig. 1a , Supplementary Notably, despite adequate solubility at day 0, there was a dramatic drop in peak intensity and the appearance of new resonances for celastrol dissolved in PBS with 50% DMSO-d6 after 7 and 14 days of incubation (Supplementary Fig. 1e-g ). The emergence of new peaks that increase in intensity over time, including in the aromatic region, points to reactions of celastrol with other molecules in solution, most likely with molecules resulting from the reaction of DMSO in aqueous solution (17). When celastrol was further diluted in PBS to 10% or 5% DMSO-d6, the occurrence of these additional peaks diminished, but the reduction of the parent compound was confounded with poor solubility. LC-MS analyses confirmed the reduction in solubility as well as the poor stability of celastrol in aqueous buffers (Supplementary Table 2) . Notably, by adding the complexing agent beta-cyclodextrin (45% in PBS), we could increase the stability of celastrol incubated for 7 or 14 days at 37°C. Overall, however, the best solvent for celastrol appears to be 100% DMSO, all tested aqueous solutions either showed decreased stability at days 7 and 14 and/or decreased solubility at day 0. Pure DMSO is nevertheless toxic to mice, especially when given chronically. Accordingly, to minimize toxic side effects, we daily prepared fresh celastrol dissolved in 1% DMSO for all injection studies.
Celastrol induces hypophagia and weight loss
To identify the mechanism(s) by which celastrol achieves weight loss, we administered celastrol (100 µg/kg, ip) once daily for 6 days and observed significantly reduced body weight, fat mass and lean mass in HFD-fed diet-induced obese (DIO, Fig. 1a ,b, Supplementary Fig. 2a ; age 36 ± 1 weeks; 32 weeks of HFD feeding) and chow-fed mice (Fig. 1c,d , Supplementary Fig. 2b ; age 36 ± 1 weeks). Celastrol treatment reduced food intake in DIO mice (Fig. 1e ) and there was a trend in the same direction in chow-fed mice (Fig. 1f) . The decrease in FI in DIO mice was delayed, with maximum efficacy occurring 9 to 12 h after celastrol administration (Supplementary Fig. 2c-e) , suggesting a celastrol-dependent alteration of gene expression.
Decreased respiratory exchange ratios and locomotory patterns were temporally correlated with reduced food intake ( Supplementary Fig. 2f-h ). Overall, we observed proportionally greater weight loss in direct linear correlation to body weight in all mice tested, regardless of chow or HFD feeding (Fig. 1g) ; i.e. heavier mice lost the most weight, while lean mice lost little to no weight.
Celastrol-induced weight loss requires functional leptin signaling in adult mice
Contrary to reports using 10-to 30-fold higher doses (2,3), but consistent with the findings of Liu and colleagues, celastrol (100 µg/kg) did not decrease BW, fat nor lean mass in 8-wk-old chow-fed leptin receptor-deficient Lep db mice (Fig. 2a-c, Supplementary Fig. 3a ). Functionality of celastrol was confirmed by a reduction of BW (Fig. 2a) as well as fat and lean mass (Fig. 2c) in age-matched chow-fed lean C57Bl/6J (WT) controls with a mean BW of 23.5 g ( Supplementary Fig. 3a ). Similarily, celastrol had no weight loss efficacy in 14-wk-old chowfed leptin-deficient Lep ob mice, but decreased BW, fat and lean mass in age-matched chow-fed WT controls (Fig. 2d ,e,f) with a BW of 30.6 g ( Supplementary Fig. 3b ). Celastrol treatment for 6 days further improved glucose tolerance in chow-fed WT but not in celastrol-injected Lep ob mice ( Fig. 2g,h ).
To assess whether effects of 100 µg/kg celastrol on BW, FI and body composition are indeed strictly leptin-dependent, we administered vehicle or leptin to a group of young (age 6 wk) chow-fed Lep ob mice ( Supplementary Fig. 3c ).
In contrast to what occurred in aged mice, there was reduced weight gain in Lep ob mice treated with celastrol, compared to vehicle-treated Lep ob mice, and this was reflected by significantly reduced fat and lean mass ( Supplementary Fig.   3d ,e). These celastrol-treated Lep ob mice also had reduced food intake compared to vehicletreated controls ( Supplementary Fig. 3f ). Our data are thus consistent with an earlier report that shows temporary weight reduction in young Lep ob mice (1), indicating that celastrol's leptin sensitizing activity may be age-dependent. Alternatively, since young Lep db mice had no weight loss in response to celastrol treatment ( Fig. 2b and (1)), it appears plausible that celastrol may temporarily increase the constitutive activity of the LepRb, or its affinity for alternative cytokines (1). .
To identify celastrol's first-order targets, we next assessed key hypothalamic signaling networks that orchestrate glucose and energy homeostasis. Surprisingly, celastrol administration to DIO mice (age 36 ± 1 wk, 32 wk on HFD) significantly increased Agouti-related protein (AgRP) mRNA expression while having no effect on mRNA expression of other neuropeptides and components of leptin and melanocortin signaling ( Supplementary Fig. 4a,b) . Moreover, celastrol had little impact on mRNA levels of genes involved in hypothalamic ER stress and hypothalamic inflammation (Supplementary Fig. 4c ). The nearly identical and somewhat paradoxical increase in hypothalamic AgRP expression after celastrol treatment has already been reported by Liu et al. (1) , which makes it unlikely to be a coincidence or artefact. Rather, it might be a counterregulatory response to the negative energy balance of celastrol-treated mice.
Overall, however, the reason for the increase in AgRP mRNA levels remains elusive. 
Celastrol-induced weight loss is unperturbed by global PTP1B deletion
JAK-STAT feedback inhibition is mediated by protein tyrosine phosphatases (PTPs), which are long-recognized anti-obesity drug targets (18). PTP1B was the first PTP linked to leptin signaling (19), and the PTP1B inhibitor and leptin sensitizer trodusquemine shares structural similarities with celastrol (20). We thus assessed whether celastrol mediates leptin resensitization via inhibition of PTP1B. We first assessed celastrol-induced weight loss in PTP1B WT and KO littermates with similar initial body weights ( Supplementary Fig. 4d ) that were exposed to the chow diet (age 22 ± 7 wk). Chow-fed PTP1B KO mice had more weight loss upon celastrol treatment than WT littermates (Fig. 3f) , and this was accompanied by nonsignificant decreases in fat and lean mass in PTP1B KO mice, and a significant loss of lean mass in WT mice (Fig. 3g) . Similarly, when the same cohort of mice was subsequently exposed to HFD for 10 wk, celastrol induced weight loss in both PTP1B WT and KO mice (Fig. 3h) , and this was largely explained by concomitant decreases in fat and lean mass (Fig. 3i) . Notably, in contrast to earlier studies (21) (22) reporting protection from DIO in PTP1B-deficient mice, we observed similar body weights; i.e., there was a similar propensity for DIO in WT and PTP1B
littermates exposed to 10 wk of HFD ( Supplementary Fig. 4e ).
Celastrol-induced weight loss is independent from UCP1-driven thermogenesis
We next assessed whether celastrol can facilitate weight loss via uncoupling protein 1 (UCP1)- and Ucp1 in BAT, and of heat shock factor protein-1 (Hsf1) and uncoupling protein-1 (Ucp1) in iWAT ( Fig. 4a) , as well as to higher UCP1 protein levels in BAT (Fig. 4b) . However, transcription of Pgc1-α and key thermogenic genes was unaffected in iWAT and BAT ( Supplementary Fig. 5a ,b). Celastrol had also no cell-autonomous thermogenic effects on C2C12 muscle cells in vitro ( Supplementary Fig. 5c,d ), and did not induce mitochondrial genes or genes involved in non-shivering thermogenesis in skeletal muscle in vivo ( Supplementary   Fig. 5e,f) .
Despite elevated UCP1 levels in iWAT and BAT, there was no impact of celastrol treatment in DIO mice on energy expenditure, basal metabolic rate or maximal norepinephrine-induced respiration under ambient housing or thermoneutral conditions of 23°C and 30°C, respectively, ( Fig. 4c,d ; age 24 wk, 20 wk HFD exposure). Similarly, pair-feeding vehicle-treated DIO mice to the average food consumption of celastrol-treated DIO mice resulted in the same decrease in body weight (Fig. 4e, Supplementary Fig. 5g ) as well as in fat and lean mass (Fig. 4f ), compared to ad libitum-fed vehicle-treated DIO mice (age 16 wk, 12 wk on HFD). These data suggest that the reduction of food intake ( Fig. 4g ) is likely the main driver for celastrol-induced loss of lean mass, thus arguing against putative toxic effects of celastrol on lean mass. Moreover, DIO UCP1-deficient mice and isogenic DIO WT mice had comparably decreased BW, fat mass and FI in response to celastrol administration (Fig. 4h-j, Supplementary Fig. 5h ; age 44 ± 4 wk, 34
wk of HFD). Collectively, these results strongly argue that celastrol-induced BW reduction is not mediated by UCP1-mediated mitochondrial uncoupling and thermogenesis.
Discussion
Ideal treatment strategies against obesity will entail both a reduction in food intake and the expenditure of excessive energy via thermogenesis. While the former is a centrally mediated process, the latter results from increased heat production by peripheral thermogenic tissues such as white or brown adipose tissue and skeletal muscle. Celastrol has recently emerged as a promising anti-obesity drug that can induce both hypophagia due to unprecedented in vivo leptin resensitization properties (1), as well as to iWAT browning and BAT UCP1 levels (6). Our results are consistent with these reports, revealing a concomitant increase in UCP1 levels in iWAT and BAT of mice treated with celastrol, and celastrol-induced weight loss that is due to a partially leptin-dependent decrease in food consumption. However, follow-up experiments revealed comparable BW loss and hypophagia in UCP1 KO and WT mice treated with celastrol, implying that UCP1-mediated thermogenesis is not a major driver for the body weight-lowering effects of celastrol.
The lack of celastrol-induced weight loss in adult Lep ob and Lep db mice suggests that celastrolinduced reduction of food intake is strictly leptin-dependent. Nevertheless, we found considerable celastrol-induced hypophagia and weight loss in 6-wk-old leptin-deficient mice.
This is consistent with a previous report of metabolic improvements of celastrol administered at a higher dose (1 mg/kg BW, ip) in 8-wk-old leptin receptor-deficient Lep db mice (2), or with a temporary weight loss in young Lep ob mice which nevertheless disappeared after prolonged lowdose celastrol treatment (1) . These data highlight the plurality of celastrol's catabolic actions which may include the sensitization of CNS LepRb signaling as well as non-leptin-driven mechanisms. In this context, one should further note that our current definition of leptin resistance is largely based on the failure of exogenous leptin to reduce food intake and body weight. On a molecular level, however, the definition of leptin resistance largely remains an enigma, with one recent report even questioning the existence of resistance against endogenous leptin signaling (23).
A putative molecular player in the development of leptin resistance is leptin negative feedback regulator PTP1B. Celastrol was recently reported to have direct inhibitory activity against PTP1B in an in vitro phosphatase assay (14) . However, we found celastrol-induced weight loss in both WT and global PTP1B deficient mice, indicating that there are PTP1B-independent mechanisms of celastrol action. However, the high sequence homology between PTP1B and T- In summary, our results in UCP1 loss-of-function models argue against celastrol-induced iWAT or BAT browning and UCP1-dependent or independent thermogenesis (25-28) as being the primary cause of the observed weight loss due to celastrol. Rather, the major impact of celastrol on weight loss appears to be driven via the CNS control of food intake. Age or a putative sensitization of LepRb signaling appear to be key factors for the lack of catabolic actions of celastrol in adults, but for normal weight loss in young Lep ob mice. However, the mode of action and exact role of leptin signaling remain elusive. Overall, we corroborate the considerable potential of celastrol as an anti-obesity drug. A pair-feeding study revealed that the loss of body adiposity, and minor loss of lean mass after celastrol treatment was solely driven by a reduction in food intake. Accordingly, celastrol appears safe and efficacious in preclinical models of obesity as well as in lean mice. These discoveries encourage reconsideration of leptin sensitizers as drugs against metabolic dysfunction. Moreover, by delineating the molecular action of celastrol, we may be able to shed new light on the enigma that is leptin resistance.
TOF-MS measurements. K.P., S.C.S., D.G.K., E.K., S.C.W., S.E.S., C.C., T. (e,f) Mean daily food intake (FI) was assessed over a period of 6 days in (e) DIO mice (7 cages) and (f) chow-fed C57BL/6J mice (2 cages) treated daily with celastrol (100 µg/kg BW) or vehicle (ip).
(g) Correlation of BW changes on study day 6 and intitial BW at day 0 in mice injected with celastrol (100 µg/kg BW; n=53).
Two-Way ANOVA with Bonferroni post-hoc tests were applied for a and c. Unpaired student ttests were used for statistical anaylses of figures b, d, e. Linear regression was applied for g.
Means ± SEM; *P<0.05; ***P<0.001; ****P<0.0001. Change on study day 6 [g] p < 0.0001 
